Co-founded by the creators of Colossal Biosciences, Astromech specializes in analyzing genomic and evolutionary data to anticipate how living systems change over time.
The company aims to shift biological research from a reactive field to a predictive one, similar to how weather forecasting uses historical patterns to project future conditions.
By reconstructing 3.8 billion years of evolutionary history, Astromech’s platform is designed to identify where species or pathogens are most vulnerable to drug resistance, disease progression, and environmental stress.
This infrastructure context is significant because it allows researchers to study how complex traits like cancer resistance and longevity emerged across different species, providing a roadmap for addressing human health and biosecurity challenges.
Moving forward, Astromech will use the new capital to expand its research team and scale the comparative genomic infrastructure used to train its models.
The company is currently moving from a deep research phase toward pilot programs with partners in health and biosecurity to validate its forecasts in real-world scenarios.
These efforts rely on a specialized technical mechanism called ancestral regulatory state reconstruction, which uses deep learning to understand how genes are controlled rather than just how they are sequenced, offering a more detailed view of biological function across the tree of life.